PA
PALI.US Palisade Bio Inc
- Market cap
- USD 201M
- P/E
- 1.2x
- P/B
- 1.79x
- ROE
- -41.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PALI.US undervalued?
Graham numberThe Graham number of Palisade Bio Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Palisade Bio Inc fundamental analysis
No fundamental analysis for Palisade Bio Inc yet.
Palisade Bio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agre…
Full company profilePalisade Bio Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Palisade Bio Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 16.2K | 260K | 260K | 15.4K | 13.5K | 0.00 | 250K | 250K | 0.00 | 0.00 | 667K |
| Gross Profit | 16.2K | 260K | 1.25M | 15.4K | -146K | -168K | -167K | 250K | -3.00K | -3.00K | - |
| Operating Income | -20.2M | -13.2M | -8.26M | -8.63M | -9.30M | -41.9M | -15.7M | -13.1M | -14.9M | -18.1M | -50.9M |
| EBITDA | -19.6M | -15.2M | -4.73M | -8.20M | -10.1M | -24.2M | -14.2M | -12.3M | -14.4M | -16.8M | -46.4M |
| Net Income | -21.1M | -15.7M | -4.93M | -8.35M | -10.3M | -26.6M | -14.3M | -12.3M | -14.4M | -16.8M | -46.4M |
| EPS | -2,525 | -71 | -18 | -35 | -43 | -2,136 | -16 | -27 | -10 | -0.30 | -0.22 |
| Balance Sheet | |||||||||||
| Total Assets | 22.6M | 13.9M | 7.68M | 6.58M | 3.02M | 12.5M | 15.8M | 14.1M | 10.9M | 134M | 119M |
| Total Liabilities | 11.3M | 5.37M | 1.63M | 1.46M | 10.1M | 5.15M | 3.28M | 2.74M | 3.39M | 4.96M | 6.11M |
| Shareholders' Equity | 11.3M | 8.52M | 6.05M | 5.13M | -7.10M | 7.37M | 12.5M | 11.3M | 7.49M | 129M | 112M |
| Cash & Short-term Investments | 20.2M | 11.7M | 5.79M | 5.11M | 729K | 10.5M | 12.4M | 12.4M | 9.82M | 133M | 114M |
| Total Debt | 3.71M | - | 5.04M | 289K | 1.42M | 199K | 404K | 369K | 169K | 71.0K | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -15.6M | -13.4M | -7.69M | -7.26M | -4.77M | -14.8M | -13.4M | -11.1M | -12.2M | -10.8M | -31.0M |
| Capital Expenditure | 161K | 94.0K | 1.71K | 6.00K | 6.00K | 0.00 | 10.0K | 4.00K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -15.8M | -13.5M | -7.69M | -7.26M | -4.77M | -14.8M | -13.4M | -11.1M | -12.2M | -10.8M | -31.0M |
| Ratios | |||||||||||
| ROE | -186.0% | -184.0% | -81.4% | -162.9% | - | -361.4% | -114.3% | -108.7% | -192.7% | -13.0% | -41.3% |
| ROA | -93.2% | -112.8% | -64.1% | -126.9% | -341.9% | -212.7% | -90.5% | -87.5% | -132.7% | -12.5% | -39.1% |
| Net Profit Margin | -129,724.2% | -6,025.4% | -1,894.2% | -54,254.9% | -76,346.2% | - | -5,704.0% | -4,920.0% | - | - | -6,959.4% |
| Debt to Equity | 0.33x | - | 0.83x | 0.06x | - | 0.03x | 0.03x | 0.03x | 0.02x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Palisade Bio Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 99.0K | 7.94 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:15 on Apr 8, 2024.
Who owns Palisade Bio Inc
- Insiders 5.08%
- Institutions 94.92%
- Public & others 0.00%
- Shares outstanding 179M
- Free float 139M
Top funds holding PALI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 5.90M | 3.38% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discv A(acc)USD | 3.95M | 2.26% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 3.92M | 2.24% | 0.00% | Oct 2026 |
| abrdn Life Sciences Investors | 3.18M | 1.82% | +39.53% | Oct 2026 |
| Federated Hermes Kaufmann Small Cap A | 3.14M | 1.80% | 0.00% | Sep 2026 |
| Biotech Growth Ord | 2.33M | 1.34% | 0.00% | Jul 2026 |
| Franklin Biotechnology Discovery A | 2.12M | 1.21% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 1.62M | 0.93% | +0.58% | Aug 2026 |
| iShares Russell 2000 Value ETF | 1.21M | 0.69% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 892K | 0.51% | +5.48% | Sep 2026 |
| Fidelity Extended Market Index | 788K | 0.45% | +7.80% | Sep 2026 |
| iShares Micro-Cap ETF | 465K | 0.27% | 0.00% | Oct 2026 |
| Simplify Propel Opportunities ETF | 434K | 0.25% | 0.00% | Oct 2026 |
| Vanguard US Momentum Factor ETF | 394K | 0.23% | 0.00% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 385K | 0.22% | +0.03% | Oct 2026 |
| Schwab Small Cap Index | 381K | 0.22% | +6.09% | Sep 2026 |
| Truvalue Glb Phrmctl Blgcl Eq (QDII) A | 323K | 0.19% | -41.06% | Jun 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 276K | 0.16% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 274K | 0.16% | -0.05% | Sep 2026 |
Top institutions holding PALI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Soleus Capital Management, L.P. | 13.1M | 7.48% | 0.00% | Jun 2026 |
| B Group, Inc | 11.4M | 6.54% | 0.00% | Jun 2026 |
| Ameriprise Financial Inc | 11.1M | 6.35% | -3.73% | Jun 2026 |
| Jupiter Topco LLC | 10.7M | 6.12% | 0.00% | Jun 2026 |
| BlackRock Inc | 10.4M | 5.98% | +456.23% | Jun 2026 |
| Octagon Capital Advisors LP | 10.3M | 5.88% | 0.00% | Jun 2026 |
| Perceptive Advisors LLC | 8.43M | 4.82% | -5.63% | Jun 2026 |
| RA Capital Management, LLC | 7.12M | 4.08% | 0.00% | Jun 2026 |
| Franklin Templeton Inc | 5.79M | 3.31% | 0.00% | Jun 2026 |
| Point72 Asset Management, L.P. | 5.25M | 3.01% | +1,175.80% | Jun 2026 |
| Boxer Capital Management, LLC | 4.80M | 2.75% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 4.50M | 2.58% | 0.00% | Jun 2026 |
| Eversept Partners, LP | 4.18M | 2.40% | -16.13% | Jun 2026 |
| Geode Capital Management, LLC | 3.76M | 2.15% | +143.20% | Jun 2026 |
| Wellington Management Company LLP | 3.70M | 2.12% | +27.51% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.58M | 2.05% | -33.42% | Jun 2026 |
| Federated Hermes Inc | 3.14M | 1.80% | 0.00% | Jun 2026 |
| Squadron Capital Management LLC | 3.00M | 1.72% | 0.00% | Jun 2026 |
| Propel Bio Management LLC | 2.58M | 1.48% | +131.60% | Jun 2026 |
| Vestal Point Capital LP | 2.50M | 1.43% | 0.00% | Jun 2026 |
Palisade Bio Inc company profile
- Company name
- Palisade Bio Inc
- Ticker
- PALI.US
- Exchange
- USA Stocks
- Listed since
- Dec 20, 2006
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- December
- Address
- 4600 South Syracuse Street, Denver, CO, United States, 80237
- Phone
- 858 704 4900
- Website
- palisadebio.com
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Palisade Bio Inc management
10- Mr. J. D. FinleyCEO, CFO & Director · born 1958
- Dr. Mitchell Lawrence Jones M.D., Ph.D.President & Chief Medical Officer · born 1977
- Mr. Ramesh C. Donthamsetty C.F.A.Head of IR and Corporate Strategy
- Julien E. CapersGeneral Counsel & Corporate Secretary
- Dr. Joerg Heyer Ph.D.Head of Translational Science & Medicine
- Dr. James Izanec M.D.Head of Clinical Development
- Mr. Daniel J. LarkinsHead of Global Regulatory Affairs
- Mr. Adarsh Patel M.B.A., M.S.Head of Chemistry, Manufacturing & Controls
- Ms. Dawn LouroHead of Clinical Operations
- Mr. Ryker WillieHead of Finance & Corporate Controller